Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy (Q35937418)

11 August 2017

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy (English)

1 reference

11 August 2017

phase I clinical trial

0 references

malaria

0 references

Plasmodium vivax

0 references

Plasmodium vivax malaria

1 reference

1 reference

Jetsumon Sattabongkot

4

object named as

Jetsumon Sattabongkot

1 reference

11 August 2017

22

W Ripley Ballou

1 reference

11 August 2017

25

Johan Vekemans

1 reference

11 August 2017

Christian F Ockenhouse

26

object named as

Christian F Ockenhouse

1 reference

11 August 2017

10

Michele D Spring

1 reference

11 August 2017

Jason W Bennett

1

1 reference

11 August 2017

Anjali Yadava

2

1 reference

11 August 2017

Donna Tosh

3

1 reference

11 August 2017

Jack Komisar

5

1 reference

11 August 2017

Lisa A Ware

6

1 reference

11 August 2017

William F McCarthy

7

1 reference

11 August 2017

Jessica J Cowden

8

1 reference

11 August 2017

Jason Regules

9

1 reference

11 August 2017

Kristopher Paolino

11

1 reference

11 August 2017

Joshua D Hartzell

12

1 reference

11 August 2017

James F Cummings

13

1 reference

11 August 2017

Thomas L Richie

14

1 reference

11 August 2017

Joanne Lumsden

15

1 reference

11 August 2017

Edwin Kamau

16

1 reference

11 August 2017

Jittawadee Murphy

17

1 reference

11 August 2017

Cynthia Lee

18

1 reference

11 August 2017

Falgunee Parekh

19

1 reference

11 August 2017

Ashley Birkett

20

1 reference

11 August 2017

Joe Cohen

21

1 reference

11 August 2017

Mark E Polhemus

23

1 reference

11 August 2017

Yannick F Vanloubbeeck

24

1 reference

11 August 2017

language of work or name

English

0 references

publication date

26 February 2016

1 reference

PLoS Neglected Tropical Diseases

11 August 2017

1 reference

11 August 2017

10

1 reference

11 August 2017

e0004423

1 reference

11 August 2017

2

1 reference

Creative Commons CC0 License

11 August 2017

start time

26 February 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted, dedicated to the public domain by copyright holder

0 references

cites work

Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

A long neglected world malaria map: Plasmodium vivax endemicity in 2010

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Determinants of relapse periodicity in Plasmodium vivax malaria

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

From the circumsporozoite protein to the RTS, S/AS candidate vaccine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

The pathophysiology of vivax malaria

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Vivax malaria: neglected and not benign

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Rationale for the development of an engineered sporozoite malaria vaccine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769081

10.1371/JOURNAL.PNTD.0004423

24 September 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference